Aeterna Zentaris to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 09 2020 - 8:00AM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a
specialty biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests, today announced that Dr. Klaus
Paulini, Chief Executive Officer of Aeterna will present at the
H.C. Wainwright 22nd Annual Global Investment Conference on
Wednesday, September 16, 2020 at 11:00 AM EDT.
In addition to the presentation, management will
also be available to participate in virtual one-on-one meetings
with qualified members of the investor community who are registered
to attend the conference. For more information, please visit the
conference website here.
A live video webcast of the presentation will be
available on the Events and Presentations page in the Investors
section of the Company’s website (www.zentaris.com). The video
webcast replay will be made available two hours following the event
and will be archived for 90 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests. The Company’s lead product,
Macrilen™ (macimorelin), is the first and only U.S. FDA and
European Commission approved oral test indicated for the diagnosis
of adult growth hormone deficiency (AGHD). Macrilen™ is currently
marketed in the United States through a license agreement with Novo
Nordisk and Aeterna Zentaris receives double-digit royalties on
sales. Aeterna Zentaris owns all rights to macimorelin outside of
the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical
success and compelling safety profile of macimorelin to develop it
for the diagnosis of child-onset growth hormone deficiency (CGHD),
an area of significant unmet need.
The Company is actively pursuing business
development opportunities for the commercialization of macimorelin
in Europe and the rest of the world, in addition to other
non-strategic assets to monetize their value. For more information,
please visit www.zentaris.com and connect with the Company on
Twitter, LinkedIn and Facebook.
Investor Contact:
Jenene Thomas JTC Team T (US): +1 (833) 475-8247
E: aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024